ReadyVax

Name: ReadyVax
Author: Emory University

Emory University

DOCUMENTED

Published in academic literature

For:Clinicians & Healthcare ProfessionalsGeneral Public & Enthusiasts

Free

Get it on Google Play

App Summary

ReadyVax is a mobile reference app designed for both healthcare providers and the general public, delivering regularly updated, evidence-based information on vaccine recommendations, schedules, and safety. The associated research describes the app's development by academic experts to provide a trustworthy resource, reporting its initial adoption by 5,142 unique users across 102 countries. By consolidating expert-vetted data and enabling real-time updates, the authors conclude the app serves as a reliable tool for both clinical and public use, especially during outbreaks.

App Screenshots

Detailed Description

Functionality & Mechanism

Developed by academic experts, ReadyVax is a mobile reference tool that delivers evidence-based vaccine information. Upon launch, the system automatically downloads the most current data, ensuring offline accessibility. The interface facilitates one-click customization, tailoring content presentation for either healthcare providers or the public. Core modules provide information on vaccine schedules, safety profiles, and vaccine-preventable diseases, supplemented by frequently asked questions, real-time news alerts, and links to authoritative resources.

Evidence & Research Context

The app was developed to provide a trustworthy, evidence-based mobile resource on vaccines for healthcare providers, pharmacists, and patients.
Associated research describing the app's development and initial adoption documented 5,142 unique user downloads across 102 countries between 2015 and 2016.
During this initial 20-month period, the user base initiated 6,841 sessions, comprising 15,491 total screen views.

Intended Use & Scope

ReadyVax is designed as a clinical and public-facing reference tool for healthcare providers, pharmacists, and patients seeking evidence-based vaccine information. Its primary utility is the rapid retrieval of data on schedules, safety, and disease prevention. The tool is informational and does not provide clinical decision support or replace professional medical consultation.

Studies & Publications

1 publication

Peer-reviewed research associated with this app.

Development/Design Paper

ReadyVax: A new mobile vaccine information app

Bednarczyk et al. (2017) · Human Vaccines & Immunotherapeutics

Describes the research-driven development of this app

Vaccine information of varying quality is available through many different sources. We describe the creation, release and utilization of ReadyVax, a new mobile smartphone app providing access to trustworthy, evidence-based vaccine information for a target audience of healthcare providers, pharmacists, and patients (including parents of children). We describe the information content and technical development of ReadyVax. Between the hard launch of the app on February 12, 2015 and October 8, 2016, the app has been downloaded by 5,142 unique users, with 6,841 total app sessions initiated, comprising a total of 15,491 screen views (2.3 screens/session on average). ReadyVax has been downloaded by users in 102 different countries; most users (52%) are from the United States. We are continuing outreach efforts to increase app use, and planning for development of an Android-compatible version of ReadyVax, to increase the available market for the app.

In the Media

Emory Technology Listing

The Emory Preparedness and Emergency Response Research Center (PERRC) developed ReadyVax to combat declining vaccination rates caused by false information online, using a standalone smartphone app that stores essential content directly on devices. The app targets physicians, pharmacists, and the general public by providing vaccine information and pushing out audience-specific informational alerts and updates. ReadyVax ensures continuity of service during limited network connectivity by storing core elements locally rather than requiring online access.

TechnologypublisherRead article